STOCK TITAN
  1. Home
  2. News
  3. ALIM

Alimera Sciences Inc. - ALIM STOCK NEWS

Welcome to our dedicated news page for Alimera Sciences (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alimera Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alimera Sciences's position in the market.

News
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Alimera Sciences, Inc. announces inducement grants under the 2024 Equity Inducement Plan for new executive appointments, including restricted stock units and stock options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
none
-
News
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Rhea-AI Summary
Alimera Sciences, Inc. announces the initiation of a randomized clinical trial studying ILUVIEN for the prevention of visual acuity loss due to radiation retinopathy. The study aims to evaluate the effectiveness of faricimab injections versus observation in patients with primary choroidal melanoma undergoing plaque brachytherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
News
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) reports impressive Q4 net revenue growth of 88% to $26.3 million and full-year net revenue up 49% to $80.8 million in 2023. The company also raises its 2024 revenue guidance, showcasing strong performance in marketing ILUVIEN and YUTIQ products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
earnings
News
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
Rhea-AI Summary
Alimera Sciences, Inc. (ALIM) will report its fourth quarter and full year 2023 financial results on March 7, 2024, before the market opens. A conference call will be held at 9:00 AM ET on the same day to discuss financial results and corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
conferences earnings
-
News
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
Rhea-AI Summary
Alimera Sciences, Inc. (ALIM) announces that the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending that patients with a natural lens being treated for chronic diabetic macular edema (DME) have access to ILUVIEN, a sustained-release treatment lasting up to 36 months. This recommendation could potentially benefit up to 75% of the overall DME population in the United Kingdom. NHS England and NHS Wales are expected to provide funding for this guidance shortly after publication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
none
-
News
Alimera Completes Recruitment for the Synchronicity Study
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) has completed enrollment for the Synchronicity Study, evaluating the safety and efficacy of YUTIQ in the treatment of chronic non-infectious uveitis and related intraocular inflammation. The Phase 4 open-label study aims to provide retina specialists with a broader sense of the utility of fluocinolone acetonide in a durable intravitreal implant across a variety of patients with chronic non-infectious uveitis affecting the posterior segment. The initial readout from the study is expected in the second half of next year and could potentially benefit both YUTIQ in the United States and ILUVIEN in Europe and the Middle East.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
News
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) announced the appointment of Elliot Maltz, C.P.A., as Chief Financial Officer. Mr. Maltz brings extensive experience from public international commercial-stage companies and will play a key role in enhancing the company's growth trajectory and driving improved cash flow. The company also approved an inducement option to purchase up to 75,000 shares of common stock for Mr. Maltz.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
none
-
News
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) announced the appointment of Todd Wood as President U.S. effective immediately. Mr. Wood brings extensive commercial leadership experience from the pharmaceutical and medical device industries, including leading the eye care sales organization at Allergan. The company also granted an inducement option to purchase up to 125,000 shares of common stock to Mr. Wood.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
management
-
News
Alimera Appoints Maggie A. Pax to Its Board of Directors
Rhea-AI Summary
Alimera Sciences, Inc. (Nasdaq: ALIM) announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax brings extensive operational experience and a history of strong leadership in the life sciences industry, which will provide new and unique perspectives as Alimera continues to scale. Her appointment comes at an exciting stage of growth for Alimera, following the acquisition of YUTIQ in the U.S. and continued expansion in international markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
management
News
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology
Rhea-AI Summary
Alimera Sciences, Inc. announces that clinical data for ILUVIEN® will be featured in three posters and a presentation at the American Academy of Ophthalmology’s 127th Annual Meeting. The data comes from the PALADIN study, which evaluates the long-term safety of ILUVIEN for patients with diabetic macular edema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
Stock ALIM logo
Alimera Sciences Inc.

Nasdaq:ALIM

ALIM Rankings

#3809 Ranked by Market Cap
#4298 Ranked by Stock Gains
N/A Ranked by Dividends

ALIM Stock Data

187.43M
8.06M
8.75%
91.96%
0.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Alpharetta

About ALIM

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.